Home » Topics » Regulatory » EMA

EMA
RSS

Isarna Therapeutics' ISTH-0036 receives E.U. orphan drug designation

May 22, 2015

Pluristem's PLX program selected for EMA's Adaptive Pathways pilot project

May 19, 2015

EMA committee recommends approval of new Orfadin formulations

May 8, 2015

EMA grants orphan drug designation to EspeRare's rimeporide for DMD

May 6, 2015

European orphan drug designation for Makindus' MI-100 in Stargardt's disease

May 5, 2015

Arno's AR-12 receives E.U. orphan drug status for cryptococcosis and tularemia

May 4, 2015

Astellas launches Cresemba in the U.S. for invasive aspergillosis and invasive mucormycosis

April 28, 2015

Daiichi Sankyo's edoxaban recommended for stroke prevention in Europe

April 28, 2015

EMA classifies NeoStem's NBS-20 as advanced therapeutic medicinal product

April 28, 2015

European committee recommends approval of Hetlioz for non-24-hour sleep-wake disorder

April 27, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...